ES2043901T3 - Adyuvante para la terapia inmunologica del cancer. - Google Patents

Adyuvante para la terapia inmunologica del cancer.

Info

Publication number
ES2043901T3
ES2043901T3 ES89101424T ES89101424T ES2043901T3 ES 2043901 T3 ES2043901 T3 ES 2043901T3 ES 89101424 T ES89101424 T ES 89101424T ES 89101424 T ES89101424 T ES 89101424T ES 2043901 T3 ES2043901 T3 ES 2043901T3
Authority
ES
Spain
Prior art keywords
adjuvant
cancer
immunological therapy
agent
immunological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89101424T
Other languages
English (en)
Inventor
Masaaki C O Keio Uni Tachibana
Hiroshi C O Keio Univer Tazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Morinaga Milk Industry Co Ltd
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Morinaga Milk Industry Co Ltd, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Application granted granted Critical
Publication of ES2043901T3 publication Critical patent/ES2043901T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A UN ADYUVANTE PARA INMUNOTERAPIA DEL CANCER CON UN AGENTE INMUNOACTIVADOR, QUE COMPRENDE UN FACTOR ESTIMULANTE DE COLONIAS COMO INGREDIENTE ACTIVO, QUE PUEDE AUMENTAR CONSIDERABLEMENTE EL EFECTO ANTITUMORAL DE DICHO AGENTE INMUNOACTIVADOR.
ES89101424T 1988-01-29 1989-01-27 Adyuvante para la terapia inmunologica del cancer. Expired - Lifetime ES2043901T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63017423A JPH01193227A (ja) 1988-01-29 1988-01-29 癌免疫療法補助剤

Publications (1)

Publication Number Publication Date
ES2043901T3 true ES2043901T3 (es) 1994-01-01

Family

ID=11943603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89101424T Expired - Lifetime ES2043901T3 (es) 1988-01-29 1989-01-27 Adyuvante para la terapia inmunologica del cancer.

Country Status (7)

Country Link
US (1) US5254534A (es)
EP (1) EP0326149B1 (es)
JP (1) JPH01193227A (es)
KR (1) KR0131204B1 (es)
CA (1) CA1336399C (es)
DE (1) DE68908426T2 (es)
ES (1) ES2043901T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
ATE324888T1 (de) * 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd COMBINED TREATMENT AGAINST CANCER
EP1309373A2 (en) * 2000-08-11 2003-05-14 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8053234B2 (en) 2007-04-27 2011-11-08 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
AU2008243343C9 (en) * 2007-04-27 2015-03-19 Bavarian Nordic A/S Induction of dendritic cell development with Macrophage-Colony Stimulating Factor (M-CSF)
AU2009212787B2 (en) * 2007-04-27 2015-03-26 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
US8445275B2 (en) 2007-04-27 2013-05-21 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
DE102014014993B4 (de) 2014-10-09 2017-02-02 Helga Schmetzer Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1

Also Published As

Publication number Publication date
EP0326149A2 (en) 1989-08-02
US5254534A (en) 1993-10-19
EP0326149A3 (en) 1990-04-18
CA1336399C (en) 1995-07-25
JPH01193227A (ja) 1989-08-03
KR890011612A (ko) 1989-08-21
KR0131204B1 (ko) 1998-04-17
DE68908426D1 (de) 1993-09-23
EP0326149B1 (en) 1993-08-18
DE68908426T2 (de) 1994-01-05

Similar Documents

Publication Publication Date Title
ES2043901T3 (es) Adyuvante para la terapia inmunologica del cancer.
BR112018069251A2 (pt) métodos de intervenção precoce para prevenir ou melhorar a toxicidade
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
ES2051800T3 (es) Tableta cubierta de dihidropiridina.
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
AR004445A1 (es) Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada
ES2053510T3 (es) Analogos de rebecamicina.
ES2170771T3 (es) Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2084827T3 (es) Composiciones de vacuna mejoradas.
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
ES2090858T3 (es) Composicion que comprende una fuente de acido graso omega-3 y un estimulador de glutation para el tratamiento de trastornos inmunes e infecciones viricas.
MX2021009439A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
JOP20220071A1 (ar) سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra
ES2081366T3 (es) Uso de la il-7 en la preparacion de medicaciones para estimular la produccion de plaquetas.
ES2176197T3 (es) Sistema de administracion transdermal que contiene un acido acetilsalicilico para la terapia de trombosis y la profilaxis del cancer.
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
PE20211307A1 (es) ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
IL98310A0 (en) The pharmacological use of certain cystine derivatives
MX2024008039A (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
PH12021550617A1 (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
ECSP034766A (es) Una combinacion que comprende combretastatina y agentes anticancerigenos
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 326149

Country of ref document: ES